Swift Run Capital Management LLC cut its stake in DaVita HealthCare Partners Inc. (NYSE:DVA) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 192,602 shares of the company’s stock after selling 4,270 shares during the period. DaVita HealthCare Partners accounts for 9.5% of Swift Run Capital Management LLC’s investment portfolio, making the stock its largest position. Swift Run Capital Management LLC owned 0.09% of DaVita HealthCare Partners worth $14,892,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Checchi Capital Advisers LLC raised its stake in DaVita HealthCare Partners by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 1,556 shares of the company’s stock valued at $120,000 after buying an additional 37 shares during the period. Berkshire Asset Management LLC PA purchased a new stake in DaVita HealthCare Partners during the second quarter valued at $203,000. Candriam Luxembourg S.C.A. purchased a new stake in DaVita HealthCare Partners during the second quarter valued at $208,000. Lebenthal Asset Management LLC purchased a new stake in DaVita HealthCare Partners during the first quarter valued at $221,000. Finally, Coastline Trust Co raised its stake in DaVita HealthCare Partners by 9.9% in the second quarter. Coastline Trust Co now owns 3,215 shares of the company’s stock valued at $249,000 after buying an additional 290 shares during the period. Institutional investors own 83.55% of the company’s stock.

Institutional Ownership by Quarter for DaVita HealthCare Partners (NYSE:DVA)

Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) traded down 0.22% on Friday, hitting $62.85. 1,329,729 shares of the stock were exchanged. DaVita HealthCare Partners Inc. has a 1-year low of $61.36 and a 1-year high of $78.94. The stock has a market cap of $13.00 billion, a price-to-earnings ratio of 36.56 and a beta of 0.96. The stock’s 50-day moving average is $64.49 and its 200-day moving average is $72.37.

DaVita HealthCare Partners (NYSE:DVA) last released its earnings results on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.03. DaVita HealthCare Partners had a net margin of 2.51% and a return on equity of 16.48%. The company had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. During the same quarter in the previous year, the company earned $0.95 EPS. DaVita HealthCare Partners’s quarterly revenue was up 8.2% compared to the same quarter last year. Analysts forecast that DaVita HealthCare Partners Inc. will post $3.76 earnings per share for the current year.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 target price on the stock in a report on Tuesday, July 5th. JPMorgan Chase & Co. increased their price objective on shares of DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. Citigroup Inc. started coverage on shares of DaVita HealthCare Partners in a research report on Tuesday, September 6th. They set a “neutral” rating and a $71.00 price objective for the company. SunTrust Banks Inc. set a $66.00 price objective on shares of DaVita HealthCare Partners and gave the stock a “hold” rating in a research report on Thursday. Finally, Bank of America Corp. downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 price objective for the company. in a research report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. DaVita HealthCare Partners presently has an average rating of “Hold” and an average price target of $75.50.

In related news, COO Michael David Staffieri sold 20,262 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the transaction, the chief operating officer now owns 52,279 shares in the company, valued at approximately $3,821,072.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.10% of the company’s stock.

DaVita HealthCare Partners Company Profile

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.